Evidence analysisNovember 6, 2026Health & Science
Human medicines European public assessment report (EPAR): Vabysmo, faricimab, Date of authorisation: 15/09/2022, Revision: 11, Status: Authorised

FreedomWitness Evidence Engine: This is an AI-assisted original analysis built from the linked source and available public source context. It separates evidence from interpretation and may challenge conventional framing only where the evidence supports it. It is not a copied article.
What is established
Vabysmo is a medicine containing the active ingredient faricimab, authorized in the European Union since September 15, 2022, for treatment of certain retinal diseases affecting adults. It targets:
- Wet age-related macular degeneration (wet AMD) — a condition where abnormal blood vessels grow beneath the retina’s central part (the macula), causing leakage, swelling, and vision loss.
- Diabetic macular oedema — swelling of the macula due to diabetes-induced fluid accumulation.
- Macular oedema caused by retinal vein occlusion (RVO) — swelling from blockage of retinal vein blood flow.
Vabysmo works as a monoclonal antibody that simultaneously binds to two proteins implicated in abnormal blood vessel growth and leakage: vascular endothelial growth factor A (VEGF-A) and angiopoietin-2 (Ang-2). By blocking both, it reduces vessel growth, leakage, swelling, and inflammation in the retina.
Treated patients receive intravitreal injections—directly into the eye’s vitreous fluid—starting typically with monthly doses, later adjusted based on response. Treatment discontinuation may occur if no benefit is observed.
What the source claims
The European Medicines Agency (EMA) reports clinical trial data comparing Vabysmo with aflibercept, another established treatment for wet AMD and macular oedema, across various patient groups:
- Wet AMD: Two studies with 1,329 patients found Vabysmo given at intervals up to 16 weeks to be at least as effective as aflibercept given every 8 weeks, showing similar vision improvements measured by letters read on standard eye charts.
- Diabetic macular oedema: Two studies with 1,891 patients demonstrated comparable vision gains for Vabysmo at fixed (8-week) or variable (up to 16-week) dosing intervals versus aflibercept every 8 weeks. Improvements were sustained through two years.
- RVO-related macular oedema: Two studies with 1,282 patients showed Vabysmo as effective as aflibercept after 24 weeks of treatment, with vision improvements maintained to 72 weeks when continuing Vabysmo at extended intervals.
Regarding safety, common side effects include cataract, conjunctival bleeding, increased eye pressure, eye pain, and watery eyes. Serious but less frequent adverse effects encompass eye inflammation, retinal tears, detachment, and endophthalmitis (intraocular inflammation). Vabysmo is contraindicated in patients with eye infections or severe intraocular inflammation.
The EMA concluded that Vabysmo’s benefits outweigh its risks, approving it with ongoing pharmacovigilance and patient information measures to promote safe use.
What may be missing from the usual framing
The source focuses primarily on demonstrating non-inferiority or equivalence to aflibercept rather than superiority, possibly framing Vabysmo as an alternative rather than a breakthrough. While extended dosing intervals are noted, real-world adherence, patient preferences, or quality-of-life impacts beyond letter recognition are not detailed.
Safety data emphasize common and serious side effects but do not elaborate on long-term outcomes or rare adverse events beyond the trial periods. There is limited information on cost-effectiveness or access differences across EU countries, which can affect broader patient benefit.
The source, being the EMA’s public assessment, aligns with regulatory standards but may not fully represent clinical practice nuances, patient experiences, or comparative effectiveness in diverse populations.
Competing evidence or uncertainty
Currently, no direct evidence from sources other than EMA is provided here regarding Vabysmo efficacy or safety. Independent real-world studies, longer-term follow-up, or head-to-head comparisons with other anti-VEGF agents might offer additional insights but are not included.
Outcomes chiefly rely on visual acuity improvements (letters read), which although standard, might not capture all functional vision changes or patient-centered endpoints. Potential variability in patient response and subgroup analyses (e.g., by disease severity or comorbidities) are not presented.
Economic considerations, which influence treatment adoption and health system impact, remain unexplored in this source. Further evidence is necessary to understand how Vabysmo fits into treatment algorithms in practice.
Why it matters
Retinal diseases such as wet AMD, diabetic macular oedema, and RVO-associated macular oedema are leading causes of vision impairment and blindness globally. Effective management preserves central vision crucial for everyday tasks.
Vabysmo’s dual inhibition of VEGF-A and Ang-2 represents a therapeutic innovation, potentially offering longer dosing intervals while maintaining efficacy. Reduced injection frequency could lessen treatment burden, improve patient adherence, and decrease clinic visits, benefiting healthcare systems and patients.
Understanding both benefits and risks of new treatments like Vabysmo informs clinical choices, patient counseling, and health policy decisions to optimize visual outcomes in chronic retinal diseases.
What to verify next
- Seek real-world effectiveness data outside trial settings to confirm sustained benefits and tolerability of Vabysmo over longer periods.
- Examine comparative cost-effectiveness analyses of Vabysmo versus other anti-VEGF therapies to assess economic impact.
- Investigate patient-reported outcomes and quality-of-life measures affected by differing dosing schedules.
- Review safety monitoring data post-market authorization to detect rare or late-onset adverse effects.
- Assess guidelines and clinical practice variations in EU countries regarding Vabysmo’s role among available therapies.
Readers are encouraged to consult the original European Medicines Agency assessment for full details and updates.
Source & verification
Primary source: What's new · November 6, 2026
FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.
Continue reading

EudraGMDP database
What is established The EudraGMDP database is an established European Union (EU) information system managed by the European Medicines Agency (EMA). It serves as…

Antimicrobial resistance in the EU/EEA (EARS-Net) – Annual Epidemiological Report for 2025
Evidence Dossier: Antimicrobial Resistance Trends in the EU/EEA 2025 Antimicrobial Resistance Trends in the EU/EEA: Evidence from the 2025 EARS-Net Report What is established…

Rapid risk assessment – Carbapenem-resistant Enterobacterales, fourth update
Evidence Dossier: Carbapenem-resistant Enterobacterales (CRE) in the EU/EEA – Latest Scientific Assessment What is established Carbapenem-resistant Enterobacterales (CRE), which include bacteria such as Klebsiella…